Botanix Pharmaceuticals Promotes Paul Seaback to Chief Operating Officer

Botanix promotes Paul Seaback to Chief Operating Officer

Botanix Pharmaceuticals (ASX: BOT) has promoted Paul Seaback from Chief Technical Officer to Chief Operating Officer. The internal promotion positions the commercial dermatology company to strengthen operational execution as it scales the commercialisation of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis.

Mr Seaback joined Botanix as Chief Technical Officer in November 2024, overseeing CMC/Supply, Quality, Regulatory, Pharmacovigilance, Medical Affairs, and Tech Services. In his new role, he will oversee day-to-day operations, drive strategic initiatives, and support growth and efficiencies across key business areas. The company describes him as an accomplished biopharmaceutical executive with over three decades of industry experience.

Sofdra is the first and only new chemical entity approved by the FDA to treat primary axillary hyperhidrosis. For shareholders, the COO appointment signals leadership continuity during a critical commercialisation phase. Internal promotions reduce onboarding risk and suggest the company has built operational bench strength ahead of product launch scale-up.

What does a Chief Operating Officer do?

The Chief Operating Officer is responsible for executing the company’s strategy through operational discipline. While the CEO sets strategic direction, the COO translates that vision into day-to-day execution, managing cross-functional teams, optimising processes, and ensuring the organisation can deliver on its commercial objectives.

For a commercial-stage biotech like Botanix, operational execution is critical. The company has transitioned from regulatory approval to commercial rollout, a phase that requires scalable processes, supply chain management, and cross-functional coordination. An experienced COO reduces the risk that operational bottlenecks delay revenue generation or undermine the commercial launch.

Seaback’s track record in scaling biotech operations

Mr Seaback’s career progression spans site-level roles to corporate oversight of end-to-end supply and operations. Prior to joining Botanix, he was Chief Technical Officer at Dermavant Sciences (a Roivant company), where he developed the global CMC and technical organisation from clinical stage into a commercial entity. Dermavant was subsequently acquired by Organon, a signal of successful execution.

Before Dermavant, he held the position of VP of Operations & Supply at a company later acquired by Roche. His global leadership roles include positions at:

• Gilead
• Medicis
• Hospira
• Mayne
• Novartis (Sandoz)

He has supported the commercialisation of leading products, including:

• Sovaldi/Harvoni
• Vtama
• Solodyn
• Truvada
• Vemlidy

This track record suggests a pattern of joining pre-commercial or scaling companies that achieve acquisition or commercial success. For investors, this provides visibility into execution risk during Botanix’s own commercialisation phase.

Leadership commentary

Dr Howie McKibbon, Chief Executive Officer

“Paul Seaback is a dynamic and results-driven leader who brings deep operational expertise and a strong vision for the future. We are pleased to recognise his contributions with a well-deserved promotion to Chief Operating Officer as we continue to expand our capabilities and deliver value to our customers and shareholders.”

Mr Seaback stated: “I’m thrilled to assume this role at such an exciting time for the Company. I look forward to working with the talented and dedicated team to build on the company’s strong foundation and help drive the next phase of growth.”

What this means for Botanix shareholders

The appointment positions the leadership team to support the next phase of growth as Botanix commercialises Sofdra. Mr Seaback’s new focus areas include optimising operational performance, enhancing cross-functional collaboration, and implementing scalable processes to support the company’s long-term strategy.

Commercial-stage biotechs live or die on execution. The transition from regulatory approval to revenue generation requires operational discipline, supply chain reliability, and market access strategy. Experienced operations leadership de-risks this transition. For shareholders, the internal promotion suggests the company has built the operational capability required to scale without the risk of external leadership onboarding delays.

Sofdra presents a novel, safe and effective solution for patients who have lacked treatment options for primary axillary hyperhidrosis, a socially challenging medical condition. The leadership team is now positioned to translate that regulatory achievement into commercial performance.

Want the Next Healthcare Breakout in Your Inbox?

Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive market-moving announcements the moment they drop.